Traumatic Brain Injury, Part I. Handbook of Clinical Neurology Volume 127

Table of Contents

Section 1 Risk and Predisposition 1. Epidemiology  2. Classification of traumatic brain injury: past, present and future  3. Genetic predictors of outcome following TBI

Section 2 Pathology and Mechanisms of Traumatic Brain Injury 4. The neuropathology of traumatic brain injury  5. Cellular and Molecular Mechanisms of Injury and Spontaneous Recovery  6. Injury biomechanics, neuropathology, and simplified physics of explosive blast and impact mild traumatic brain injury  7. Cellular biomechanics of central nervous system injury  8. Animal models of traumatic brain injury

Section 3 Special Considerations 9. Mild traumatic brain injury  10. Acute sports-related traumatic brain injury and repetitive concussion  11. Brain injury from explosive blast: description and clinical management   12. Surgical management of civilian gunshot wounds to the head  13. Acute Loss of Consciousness  14. Systemic manifestations of traumatic brain injury  15. Special Considerations in Infants and Children

Section 4 Current and Emerging Diagnostic Tools 16. Biomarkers  17. Current and future diagnostic tools for traumatic brain injury: CT, conventional MRI, and diffusion tensor imaging  18. Using fMRI and EEG to detect consciousness after severe brain injury   19. Resting Functional Imaging Tools: (MRS, SPECT, PET and PCT)  20. Advances in imaging explosive blast mild traumatic brain injury  21. Electrophysiological recordings in traumatic brain injury

Section 5 Management and Treatment 22. Neuroprotection for traumatic brain injury  23. The prehospital management of traumatic brain injury  24. Acute Management of Military-Related Injury (PHI & Blast)  25. Clinical Management of the Minimally Conscious State   26. Rehabilitation after traumatic brain injury  27. Long-Term Social Integration and Community Support   28. Recent developments in clinical trials for the treatment of traumatic brain injury

Authors

Jordan Grafman Director, Brain Injury Research, Head, Cognitive Neuroscience Laboratory, Shirley Ryan Ability Lab; Professor, Department of Physical Medicine & Rehabilitation, Feinberg School of Medicine, Northwestern University, Clarkston, IL, USA. Dr. Grafman has been the director of Brain Injury Research at the Shirley Ryan AbilityLab ((SRALab)formally known as the Rehabilitation Institute of Chicago) since 2012 and is on faculty at Northwestern University's Feinberg School of Medicine in the Departments of Physical Medicine and Rehabilitation, Neurology, Psychiatry and Behavioral Sciences, and the Cognitive Neurology and Alzheimer's Disease Center as well as the Department of Psychology in the Weinberg College of Arts and Sciences. Before joining the SRALab, Dr. Grafman was briefly director of Traumatic Brain Injury Research at the Kessler Foundation in West Orange New Jersey. Prior to that appointment in 2011, Dr. Grafman was Chief of the Cognitive Neuroscience Section at the National Institute of Neurological Disorders and Stroke in Bethesda, Maryland for many years. His investigation of brain function and behavior contributes to advances in medicine, rehabilitation, and psychology, and informs ethics, law, philosophy, and health policy. His study of the human prefrontal cortex and cognitive neuroplasticity incorporates neuroimaging and genetics, an approach that is expanding our knowledge of the functions of the human frontal lobes, as well as the effects of neurological disorders that impair frontal lobe brain function. Andres M. Salazar Chairman, CEO, & Scientific Director, Oncovir, Inc., Washington, DC, USA. Andres M. Salazar, MD, is CEO, Scientific Director and cofounder of Oncovir, Inc., a pharmaceutical company developing the immunomodulator, Hiltonol® (Poly-ICLC). He is a retired US Army Colonel and formerly Professor of Neurology at USUHS. He was Director of the Vietnam Head Injury Study and Founder, Principal Investigator, and first Director of the Defense and Veterans Head Injury Program, an ongoing U.S. National Head Injury clinical management and research effort. His research background includes neurotraumatology, neurodegenerative diseases, multiple sclerosis (MS), AIDS, and Oncology. He has over 200 publications, several patents, and has conducted multiple clinical studies, including in head injury, AIDS, pilot and pivotal clinical trials of beta-interferon (Avonex) in multiple sclerosis, and clinical trials of Hiltonol® in various cancers, MS, and AIDS. Dr. Salazar is a graduate of Dartmouth College and Jefferson Medical College. He completed Neurology training at Walter Reed Army Medical Center, and a Neurovirology Fellowship at the CNSSL, National Institutes of Health, Bethesda, MD.